NASDAQ: SPRBSpruce Biosciences Inc Stock
$0.12+0.00 (+0%)
Updated Apr 17, 2025
SPRB Price
$0.12
Fair Value Price
N/A
Market Cap
$5.03M
52 Week Low
$0.11
52 Week High
$0.87
P/E
-0.09x
P/B
0.17x
P/S
3.53x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.91M
Earnings
-$53.04M
Gross Margin
100%
Operating Margin
-1,073.69%
Profit Margin
-1,079.9%
Debt to Equity
0.57
Operating Cash Flow
-$56M
Beta
1.14
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
SPRB Overview
Spruce Biosciences Incorporated develops and commercializes novel therapies for rare endocrine disorders. It is developing Tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from Congenital Adrenal Hyperplasia (CAH), which is in a Phase 2b clinical trial. Spruce Biosciences was incorporated in 2014 and is headquartered in Daly City, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SPRB's potential to beat the market
- SPRB doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SPRB
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important SPRB news, forecast changes, insider trades & much more!
SPRB News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SPRB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SPRB is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SPRB is good value based on its book value relative to its share price (0.17x), compared to the US Biotechnology industry average (4.05x)
P/B vs Industry Valuation
SPRB is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SPRB due diligence checks available for Premium users.
Valuation
SPRB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.09x
Industry
-177.72x
Market
27.98x
SPRB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.17x
Industry
4.05x
SPRB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SPRB's financial health
Profit margin
Revenue
$697.0k
Net Income
-$23.6M
Profit Margin
-3,380.1%
SPRB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SPRB's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$45.2M
Liabilities
$16.4M
Debt to equity
0.57
SPRB's short-term assets ($44.21M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SPRB's short-term assets ($44.21M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SPRB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SPRB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$20.7M
Investing
$0.0
Financing
-$625.0k
SPRB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SPRB vs Biotech Stocks
Spruce Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.